Session 5: Signalling Networks in Tumorigenesis

Sign In to gain access to subscriptions and/or personal tools.

This Article

	Free Full Text (Free PDF) Free
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map

Services

	Email this article to a friend
	Similar articles in this journal
	Alert me to new issues of the journal
	Add to Saved Citations
	Download to citation manager
	Request Permissions
	Request Reprints
	Add to My Marked Citations

Citing Articles

	Citing Articles via Google Scholar
	Citing Articles via Scopus

Google Scholar

	Search for Related Content

Social Bookmarking

	What's this?

References

Bin-Bing, S.Z., and Elledge, S.J. (2000). The DNA damage response: putting checkpoints in perspective. Nature 408, 433—9.[CrossRef][Medline] [Order article via Infotrieve]

Rouse, J., and Jackson, S.L. (2002). Interfaces between the detection, signaling and repair of DNA damage. Science 297, 547—51.[Abstract/Free Full Text]

Sawyers, C.L. (2003). Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 17, 2998—3010.[Free Full Text]

Jelinsky, S., Estep, P., Church, G., and Samson, L.D. (2000). Regulatory networks revealed by transcriptional profiling of damaged Saccharomyces cerevisiae cells: Rpn4 links base excision repair with proteasomes. Molecular and Cellular Biology 20(21), 8157—67.[Abstract/Free Full Text]

Begley, T.J., Rosenbach, A.S., Ideker, T., and Samson, L.D. (2002). Damage recovery pathways in S. cerevisiae revealed by genomic phenotyping and interactome mapping. Molecular Cancer Research 1(2), 103—12.[Abstract/Free Full Text]

Begley, T.J., Rosenbach, A.S., Ideker, T., and Samson, L.D. (2004). Damage-recovery hot spots identified by genomic phenotyping and localization mapping. Submitted.

Hickman, M.J., and Samson, L.D. (2004) Apoptotic signaling in response to a single type of DNA lesion, 06 -methylguanine. Molecular Cell, 14, 105—16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Sawyers, C.L. (2003). Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 17, 2998—3010.[Free Full Text]

Heinrich, M.C., Corless, C.L., Demetri, G.D., Blanke, C.D., von Mehren, M., Joensuu, H., McGreevey, L.S., Chen, C.J., Van den Abbeele, A.D., Druker, B.J., Kiese, B., Eisenberg, B., Roberts, P.J., Singer, S., Fletcher, C.D., Silberman, S., Dimitrijevic, S., and Fletcher, J.A. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21, 4342—9.[Abstract/Free Full Text]

Arteaga, C.L. (2002). Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res 5, 96—100.[CrossRef][Web of Science]

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R.P., and Baselga, J. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21, 2237—46.[Abstract/Free Full Text]

Kris, M.G., Natale, R.B., Herbst, R.S., Lynch, T.J., Jr., Prager, D., Belani, C.P., Schiller, J.H., Kelly, K., Spiridonidis, H., Sandler, A., Albain, K.S., Cella, D., Wolf, M.K., Averbuch, S.D., Ochs, J.J., and Kay, A.C. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 290, 2149—58.[Abstract/Free Full Text]

Giaccone, G., Herbst, R.S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R.B., Schiller, J.H., Von Pawel, J., Pluzanska, A., Gatzemeier, U., Grous, J., Ochs, J.S., Averbuch, S.D., Wolf, M.K., Rennie, P., Fandi, A., and Johnson, D.H. (2004). Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial— INTACT 1. J Clin Oncol 22, 777—84.[Abstract/Free Full Text]

Herbst, R.S., Giaccone, G., Schiller, J.H., Natale, R.B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J.A., Wolf, M.K., Krebs, A.D., Averbuch, S.D., Ochs, J.S., Grous, J., Fandi, A., and Johnson, D.H. (2004). Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22, 785—94.[Abstract/Free Full Text]

Burtness, B., Li, Y., Flood, W., Mattar, B.I., and Forastiere, A.A. (2002). Phase III trial comparing cisplatin (C) + placebo to C + anti-epidermal growth factor receptor (EGF-R) antibody C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 21, 226a.

Saltz, L., Meropol, N.J., Loehrer, P.J., Waksal, H., Needle, M.N., and Mayer, R.J. (2002). Single agent IMC-C225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 21, 127a.

Schwartz, G., Dutcher, J.P., Vogelzang, N.J., Gollob, J., Thompson, J., Bukowski, R.M., Figlin, R.A., Lohner, M., Roskos, L., Hwang, C.C., Foon, K., Schwab, G., and Rowinsky, E. (2002). Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proc Am Soc Clin Oncol 21, 24a.

Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., and Meyerson, M. (2004). EGFR Mutations in Lung Cancer: correlation with Clinical Response to Gefitinib Therapy. Science.

Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., and Haber, D.A. (2004). Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N Engl J Med.